Dovitinib has been shown to target FGFR1 in PCa in vivo, however the effects of Dovitinib on FGFR downstream signaling pathways such as STAT, AKT, and MAPK are not understood [27]. This evidence concerns the gene FGFR1 and posterior cortical atrophy.